The Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Induces Apoptosis in Medulloblastoma and Glioblastoma Cells
Authors:
Open Access
- 19 April 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4) , e18820
Abstract
Tumors of the central nervous system represent a major source of cancer-related deaths, with medulloblastoma and glioblastoma being the most common malignant brain tumors in children and adults respectively. While significant advances in treatment have been made, with the 5-year survival rate for medulloblastoma at 70–80%, treating patients under 3 years of age still poses a problem due to the deleterious effects of radiation on the developing brain, and the median survival for patients with glioblastoma is only 15 months. The transcription factor, STAT3, has been found constitutively activated in a wide variety of cancers and in recent years it has become an attractive therapeutic target. We designed a non-peptide small molecule STAT3 inhibitor, LLL12, using structure-based design. LLL12 was able to inhibit STAT3 phosphorylation, decrease cell viability and induce apoptosis in medulloblastoma and glioblastoma cell lines with elevated levels of p-STAT3 (Y705). IC50 values for LLL12 were found to be between 1.07 µM and 5.98 µM in the five cell lines expressing phosphorylated STAT3. STAT3 target genes were found to be downregulated and a decrease in STAT3 DNA binding was observed following LLL12 treatment, indicating that LLL12 is an effective STAT3 inhibitor. LLL12 was also able to inhibit colony formation, wound healing and decreased IL-6 and LIF secretion. Our results suggest that LLL12 is a potent STAT3 inhibitor and that it may be a potential therapeutic treatment for medulloblastoma and glioblastoma.Keywords
This publication has 43 references indexed in Scilit:
- Interleukin-6 in bone metastasis and cancer progressionEuropean Journal of Cancer, 2010
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences, 2007
- Interleukin-6 and its receptor: from bench to bedsideMedical Microbiology and Immunology, 2006
- IL-6 signaling via the STAT3/SOCS3 pathway: Functional Analysis of the Conserved STAT3 N-domainMolecular and Cellular Biochemistry, 2006
- c-Myc Overexpression Causes Anaplasia in MedulloblastomaCancer Research, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- STATs in oncogenesisOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986